7月，A股市场赚钱效应明显，延续前期上涨态势，A股不断创新高，沪指多次冲上3600点，量价表现上均鼓舞人心。 7月"收官战"，A股放量普跌，钢铁、有色金属、房地产有较大幅度回调。 那么，接下来的8月行情如何？ 受访人士告诉《国际金融报》记者，市场已连涨三个月，随着近两日的调整，接下来8月份大概率将呈现宽幅震荡格 局，市场或凸显"顺周期搭台，成长唱戏"的特征。 沪指失守3600点 7月31日，A股走低，午后加速下跌。最终，沪指收跌1.18%报3573.21点，创业板指收跌1.66%报2328.31点，深证成指 收跌1.73%。其他重要指数也是收跌居多，科创50、北证50跌幅均超过1%，沪深300跌1.82%，上证50跌1.54%。 交易量能上，今日放量大跌，日成交额为1.96万亿元，而上个交易日为1.87万亿元。个股收跌居多，共计4287只个股 收跌，跌停股6只；1061只个股收涨，涨停股49只。 板块收跌居多，31个申万一级行业中，仅计算机、通信板块微涨，数字认证（300579）、淳中科技（603516）涨停， 中嘉博创（000889）、剑桥科技（603083）涨停。综合、国防军工、银行、医药生物、机械设备、 ...

Core Viewpoint - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors on recent developments and potential impacts on company performance [2]. Company Announcements - Water Well Square: Director Sathish Krishnan resigned due to work reasons and will no longer hold any position in the company [3]. - Victory Energy: The company reported normal operating conditions with no significant changes in the internal or external business environment [4][5]. - Dream Network Technology: The company plans to jointly invest in a private equity fund with a target fundraising scale of 2 billion yuan, with a commitment of 50 million yuan from the company [6]. - Guoen Co., Ltd.: The company has completed the development of PEEK material production technology and aims to build a vertical integration platform for the entire PEEK industry chain [7]. - Action Education: The controlling shareholder proposed a mid-term dividend of 10 yuan per 10 shares for the 2025 fiscal year [8]. - Southern Road Machine: The company noted that its stock price has deviated from its fundamentals, indicating potential risks for investors [9]. - Shandong Highway: The company plans to participate in a capital increase project for Weihai Bank, with a total investment not exceeding 348 million yuan [11]. - Dalian Friendship: The company reached a settlement in a lawsuit with its controlling shareholder, with plans to withdraw the case [12]. - Huilv Ecology: The company plans to increase investment by 600 million yuan to build a production base in Ezhou [13]. - Qingdao Bank: The bank reported a net profit of 3.065 billion yuan for the first half of 2025, a year-on-year increase of 16.05% [14]. - Ankai Micro: The company will launch a low-power lock control SoC chip designed for smart locks [15]. - Yingweike: The company has built a complete liquid cooling technology and product solution capability [16][17]. - Dashengda: The company plans to acquire a 30% stake in Thailand Far East International Environmental Co., Ltd. for 20.4 million Thai Baht [18]. - Dongxin Co., Ltd.: The company clarified that its chip products are not intended for large model computing clusters [19]. - Tibet Tourism: The company will apply for a trading suspension if significant trading anomalies continue [20]. - New Aluminum Era: The company plans to invest at least 500 million yuan in a lightweight high-strength automotive parts project [21]. - Darui Electronics: The company plans to acquire 80% of Weiste's shares to enhance its strategic layout in lightweight materials [22]. Performance Reports - Jiejia Weichuang: The company expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, a year-on-year increase of 38.65% to 59.85% [23]. - Sinopec: The company anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year [24]. - Da Da Quan: The company reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [25]. - Zhengdan Co., Ltd.: The company reported a net profit of 630 million yuan for the first half of 2025, a year-on-year increase of 120.35% [26]. - New Light Optoelectronics: The company expects a revenue of approximately 21 million yuan for the first half of 2025, with a net loss of 19 million to 23 million yuan [27]. - Xiangfenghua: The company reported a net loss of 294,590 yuan for the first half of 2025, compared to a profit in the previous year [28]. Major Contracts - Shenlian Bio: The company signed contracts for the development of multi-valent vaccines with the Chinese Academy of Agricultural Sciences [29]. - Boying Special Welding: The company signed a cooperation framework agreement with Weirham for special welding technology applications [30]. Shareholding Changes - Jiangnan Yifan: The company's general manager plans to increase his shareholding [31]. - Jieya Co., Ltd.: Major shareholders plan to reduce their holdings by up to 4.95% [32]. - Tongda Co., Ltd.: A major shareholder plans to reduce holdings by up to 3% [34]. - Haohuan Depth: A major shareholder plans to reduce holdings by up to 2.17% [35]. - Jiahua Technology: A major shareholder plans to reduce holdings by up to 2% [36]. - Heyuan Gas: A major shareholder plans to reduce holdings by up to 2% [37]. Share Buybacks - Fuanna: The company plans to repurchase shares for an amount between 55.85 million and 104 million yuan [38]. Financing Activities - Aoshikang: The company plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [39].

Core Viewpoint - The market showed a fluctuating upward trend in July, with all three major indices closing higher for the month, particularly the ChiNext Index which rose over 8% [1] Market Performance - The Shanghai Composite Index struggled to maintain the 3600-point level, experiencing a loss by the end of the trading day [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.94 trillion, an increase of 91.7 billion compared to the previous trading day [1] Sector Performance - The innovative drug sector demonstrated strong performance, with several stocks, including Nanxin Pharmaceutical, hitting the daily limit [1] - AI application stocks were notably active, with stocks like Yidian Tianxia also reaching the daily limit [1] - AI hardware stocks showed mixed results, while the liquid cooling server concept performed strongly, with stocks such as Invec hitting the daily limit [1] Index Performance - By the end of the trading day, the Shanghai Composite Index fell by 1.18%, the Shenzhen Component Index decreased by 1.73%, and the ChiNext Index dropped by 1.66% [1]

Group 1: Clinical Trials and Approvals - Heng Rui Medicine received clinical trial approval for HRS-5041 tablets for prostate cancer treatment, a novel AR-PROTAC small molecule with potential to overcome resistance compared to second-generation AR inhibitors [1] - Microchip Biotech's CS231295 tablets received FDA approval for a Phase I clinical trial targeting advanced solid tumors, noted for its ability to penetrate the blood-brain barrier [2] - Shuyuan obtained a summary report for BDB-001 injection, showing significant clinical advantages in reducing hormone dosage for ANCA-associated vasculitis, with plans to advance to Phase III trials [5] - Huayi Pharmaceutical's HSK3486 received FDA application acceptance for marketing [12] Group 2: Financial Performance - Daodaoquan reported a 563.15% increase in net profit for the first half of 2025, with revenue of 2.792 billion yuan, driven by improved sales and reduced raw material costs [4] - China Petroleum and Chemical Corporation (Sinopec) expects a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, reflecting a decline due to falling oil prices and market competition [6] Group 3: Shareholder Actions - Wanhua Chemical's major shareholder plans to reduce its stake by up to 0.54%, equating to no more than 17 million shares, due to personal financial needs [2] - Ding Tong Technology's controlling shareholder intends to transfer 3% of the company's shares, totaling 417.6 million shares, for similar financial reasons [7] Group 4: New Projects and Investments - Guo En Co., Ltd. announced a project to establish a new platform for PEEK and polystyrene engineering materials with an investment of 960 million yuan, enhancing competitiveness in specialty engineering plastics [8] - Shanying International plans to establish a partnership with a valuation of 2.977 billion yuan to attract long-term investors, including state-owned capital [8]

Group 1: Drug Development and Clinical Trials - Heng Rui Medicine received clinical trial approval for HRS-5041, a new AR-PROTAC small molecule for prostate cancer treatment, showing significant degradation of AR proteins and potential to overcome resistance compared to second-generation AR inhibitors [1] - Huahai Pharmaceutical's HB0043, the world's first dual-target antibody for IL-17A and IL-36R, received clinical trial approval, aimed at treating various autoimmune diseases with a development cost of approximately 69.09 million yuan [4] - Microchip Biotech's CS231295, a selective AuroraB inhibitor, received FDA approval for a Phase I clinical trial targeting advanced solid tumors, with no similar drugs currently in clinical trials globally [5] - Shutai Shen's BDB-001 injection for ANCA-associated vasculitis showed significant clinical advantages in hormone reduction during Phase I/II trials, prompting plans for Phase III trials [6] - Yahui Medicine's APL-1401 for moderate to severe active ulcerative colitis showed positive preliminary results in Phase Ib trials, with plans for further evaluation in a larger patient group [8] Group 2: Corporate Actions and Financial Updates - Wanhua Chemical's major shareholder plans to reduce its stake by up to 0.54%, equivalent to 17 million shares, due to personal financial needs, with the reduction period set from August 22, 2025, to November 21, 2025 [2] - Shanying International plans to establish a partnership valued at 2.977 billion yuan to attract long-term investors, enhancing its sustainable development and core competitiveness [3] - Ding Tong Technology's controlling shareholder intends to transfer 3% of the company's shares, amounting to 417,600 shares, for personal financial needs [7] - Aokang plans to issue convertible bonds to raise no more than 1 billion yuan for high-end printed circuit board projects [9] - Ankai Micro launched the AK1037 series low-power lock control SoC chip, enhancing its product matrix in smart lock solutions [10]

（原标题：揭秘涨停丨这一板块掀起涨停潮） 以封单金额计算，10股封单资金均超亿元。其中，英维克、胜通能源、东芯股份3股封单资金均在3亿元 以上，分别为4.61亿元、3.91亿元、3.02亿元。 英维克具有液冷服务器+数据中心+英伟达概念。此前，英维克表示，目前公司服务器侧有提供液冷散 热解决方案，同时数据中心机房侧提供风冷、液冷散热解决方案，以适配各种场景的算力需求。 人工智能发展势头强劲，算力需求旺盛，推动液冷服务器成为刚需硬件。中商产业研究院报告显示， 2023年中国液冷服务器市场规模约为109亿元，同比增长49.3%。该机构预测，到2027年，中国液冷服 务器市场规模将超680亿元。 龙头点睛：液冷服务器板块多股涨停 10股封单资金均超1亿元。 涨停战场：英维克封单资金超4亿元 据证券时报·数据宝统计，今日（7月31日），从收盘涨停板封单量来看，胜通能源、文科股份、利德曼 封单量排名前三，依次为30.73万手、27.46万手、22.27万手；诺德股份、德展健康、英维克等个股封单 量均在10万手以上。 从连续涨停天数来看，西藏旅游斩获9连板，7月15日以来累计涨幅134.22%；安正时尚和中化装备等个 股 ...

Core Viewpoint - The company, Invec (002837.SZ), has reported no undisclosed significant information affecting its stock price despite increased market attention on AI, computing power equipment, and data centers [1] Group 1: Company Operations - The company has observed heightened interest in its liquid cooling business due to developments in AI and computing power [1] - The company aims to leverage its technological innovation in both air cooling and liquid cooling to expand its customer base in domestic and international data centers and computing power equipment sectors [1] - The company has established a relatively complete liquid cooling technology, product, and solution capability [1] Group 2: Market Environment - The company's production and operational conditions remain normal, with no significant changes in its main business or the internal and external operating environment [1]

Core Viewpoint - The company, Invec (002837.SZ), has experienced a significant stock price fluctuation, with a cumulative increase of over 20% in the closing prices on July 30 and July 31, 2025, indicating abnormal trading activity [1] Group 1: Stock Performance - The stock price of Invec has shown a cumulative increase of over 20% over two consecutive trading days, which is classified as abnormal trading behavior [1] - The company has confirmed that there are no undisclosed significant information affecting the stock price, despite the market's heightened interest in AI, computing power equipment, and data centers [1] Group 2: Business Focus - Invec aims to leverage its technological innovation in both air cooling and liquid cooling to expand its customer base in the domestic and international data center and computing power equipment sectors [1] - The company has established a relatively complete liquid cooling technology, product, and solution capability, positioning itself to capitalize on the ongoing development of AI computing power [1]

Core Viewpoint - The company, Yingweike (002837), has noted increased market attention on AI, computing equipment, and data center industries, particularly regarding its liquid cooling business, but has confirmed no undisclosed significant information affecting stock prices [1] Group 1: Company Operations - The company is leveraging its technological advantages in air cooling and liquid cooling to expand its customer base in domestic and international data center and computing equipment sectors [1] - The company has established a relatively complete liquid cooling technology, product, and solution capability [1] - Current production and operational conditions of the company are normal, with no significant changes in its main business or external operating environment [1]

Core Viewpoint - The stock of Invec (002837.SZ) experienced an abnormal fluctuation, with a cumulative price increase of over 20% on July 30 and 31, 2025, attributed to market interest in AI, computing power equipment, and data centers [1] Group 1: Company Information - Invec has not identified any undisclosed significant information that could have impacted its stock price following a review of public media [1] - The company aims to leverage its technological advantages in air cooling and liquid cooling to expand its customer base in the domestic and international data center and computing power equipment sectors [1] - Invec has developed a relatively complete liquid cooling technology, product, and solution chain [1]